Ask AI
ProCE Banner Activity

CE

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Slideset

Downloadable slides on the efficacy and safety of bispecific antibodies currently approved to manage relapsed/refractory multiple myeloma based on clinical trial data and guideline recommendations.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Released: May 20, 2026

Expiration: November 19, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence to optimize the identification, monitoring, and management of adverse events in patients with relapsed/refractory multiple myeloma receiving treatment with bispecific antibodies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize key toxicities such as cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, cytopenias, infections, and agent-specific effects, using current guideline-based tools and protocols

  • Interpret clinical trial data and real-world evidence to differentiate bispecific antibodies by targets, dosing strategies, safety profiles, and administration nuances, facilitating optimal agent selection and sequencing in relapsed/refractory multiple myeloma

  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements

  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations

Financial Disclosures

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Syeda Saba Kareem, PharmD, BCOP: consultant/advisor/speaker: Janssen, Pfizer, Regeneron, Sanofi.

Sara A. Scott, PharmD, BCOP: consultant/advisor/speaker: GlaxoSmithKline, Pfizer, Sanofi.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 20, 2026, through November 19, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-013-H01-P has been assigned to this home study application-based activity. This activity is approved for 0.75 contact hours (0.075 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.